OBJECTIVE: To assess the short-term effects of extended-release niacin (ERN) on endothelial function in HIV-infected patients with low high-density lipoprotein-cholesterol (HDL-c) levels. METHODS: Randomized controlled study to determine the short-term effects of ERN on endothelial function, measured by flow-mediated vasodilation (FMD) of the brachial artery, in HIV-infected adults with low HDL-c. Participants on stable HAART with fasting HDL-c less than 40 mg/dl and low-density lipoprotein-cholesterol less than 130 mg/dl were randomized to ERN or control arms. ERN treatment started at 500 mg/night and titrated to 1500 mg/night for 12 weeks. Controls received the same follow-up but were not given ERN (no placebo). Participants were excluded if they had a history of cardiac disease, uncontrolled hypertension, diabetes mellitus, or were on lipid-lowering medications such as statins and fibrates. Change in FMD was compared between arms with respect to baseline HDL-c. RESULTS:Nineteen participants were enrolled: 89% men, median age 50 years, 53% white/non-Hispanic, median CD4 cell count 493 cells/microl, and 95% of them had HIV RNA below 50 copies/ml. Participants receiving ERN had a median HDL-c (interquartile range) increase of 3.0 mg/dl (0.75 to 5.0) compared with -1.0 mg/dl in controls (-6.0 to 2.5), a P value is equal to 0.04. The median change in FMD was 0.91% (-2.95 to 2.21) for ERN and -0.48% (-2.65 to 0.98) for controls (P = 0.67). However, end of study FMD for ERN was significantly different from controls after adjusting for baseline differences in FMD and HDL-c, 6.36% (95% confidence interval 4.85-7.87) and 2.73% (95% confidence interval 0.95-4.51) respectively, a P value is equal to 0.048. CONCLUSION: This pilot study demonstrated that short-term niacin therapy could improve endothelial function in HIV-infected patients with low HDL-c.
RCT Entities:
OBJECTIVE: To assess the short-term effects of extended-release niacin (ERN) on endothelial function in HIV-infectedpatients with low high-density lipoprotein-cholesterol (HDL-c) levels. METHODS: Randomized controlled study to determine the short-term effects of ERN on endothelial function, measured by flow-mediated vasodilation (FMD) of the brachial artery, in HIV-infected adults with low HDL-c. Participants on stable HAART with fasting HDL-c less than 40 mg/dl and low-density lipoprotein-cholesterol less than 130 mg/dl were randomized to ERN or control arms. ERN treatment started at 500 mg/night and titrated to 1500 mg/night for 12 weeks. Controls received the same follow-up but were not given ERN (no placebo). Participants were excluded if they had a history of cardiac disease, uncontrolled hypertension, diabetes mellitus, or were on lipid-lowering medications such as statins and fibrates. Change in FMD was compared between arms with respect to baseline HDL-c. RESULTS: Nineteen participants were enrolled: 89% men, median age 50 years, 53% white/non-Hispanic, median CD4 cell count 493 cells/microl, and 95% of them had HIV RNA below 50 copies/ml. Participants receiving ERN had a median HDL-c (interquartile range) increase of 3.0 mg/dl (0.75 to 5.0) compared with -1.0 mg/dl in controls (-6.0 to 2.5), a P value is equal to 0.04. The median change in FMD was 0.91% (-2.95 to 2.21) for ERN and -0.48% (-2.65 to 0.98) for controls (P = 0.67). However, end of study FMD for ERN was significantly different from controls after adjusting for baseline differences in FMD and HDL-c, 6.36% (95% confidence interval 4.85-7.87) and 2.73% (95% confidence interval 0.95-4.51) respectively, a P value is equal to 0.048. CONCLUSION: This pilot study demonstrated that short-term niacin therapy could improve endothelial function in HIV-infectedpatients with low HDL-c.
Authors: Scott D Holmberg; Anne C Moorman; John M Williamson; Tony C Tong; Douglas J Ward; Kathy C Wood; Alan E Greenberg; Robert S Janssen Journal: Lancet Date: 2002-11-30 Impact factor: 79.321
Authors: J H Stein; M A Klein; J L Bellehumeur; P E McBride; D A Wiebe; J D Otvos; J M Sosman Journal: Circulation Date: 2001-07-17 Impact factor: 29.690
Authors: James H Stein; Michelle A Merwood; Jennifer L Bellehumeur; Susan E Aeschlimann; Claudia E Korcarz; Gail L Underbakke; Maureen E Mays; James M Sosman Journal: Am Heart J Date: 2004-04 Impact factor: 4.749
Authors: Annelies W E Weverling-Rijnsburger; Iris J A M Jonkers; Eric van Exel; Jacobijn Gussekloo; Rudi G J Westendorp Journal: Arch Intern Med Date: 2003-07-14
Authors: Jeffrey T Kuvin; Maria E Rämet; Ayan R Patel; Natesa G Pandian; Michael E Mendelsohn; Richard H Karas Journal: Am Heart J Date: 2002-07 Impact factor: 4.749
Authors: Maria E Rämet; Mika Rämet; Qing Lu; Moriah Nickerson; Markku J Savolainen; Amy Malzone; Richard H Karas Journal: J Am Coll Cardiol Date: 2003-06-18 Impact factor: 24.094
Authors: Nina Friis-Møller; Caroline A Sabin; Rainer Weber; Antonella d'Arminio Monforte; Wafaa M El-Sadr; Peter Reiss; Rodolphe Thiébaut; Linda Morfeldt; Stephane De Wit; Christian Pradier; Gonzalo Calvo; Matthew G Law; Ole Kirk; Andrew N Phillips; Jens D Lundgren Journal: N Engl J Med Date: 2003-11-20 Impact factor: 91.245
Authors: Michael P Dubé; Lauren Komarow; Carl J Fichtenbaum; Joseph J Cadden; Edgar T Overton; Howard N Hodis; Judith S Currier; James H Stein Journal: Clin Infect Dis Date: 2015-05-15 Impact factor: 9.079
Authors: Chunrong Lin; Andrew Grandinetti; Cecilia Shikuma; Scott Souza; Nisha Parikh; Beau Nakamoto; Kalpana J Kallianpur; Dominic Chow Journal: Hawaii J Med Public Health Date: 2013-04